These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 8345590

  • 1. Treatment of metastatic renal cell carcinoma with recombinant interleukin-2 in combination with vinblastine or lymphokine-activated killer cells.
    Kuebler JP, Whitehead RP, Ward DL, Hemstreet GP, Bradley EC.
    J Urol; 1993 Sep; 150(3):814-20. PubMed ID: 8345590
    [Abstract] [Full Text] [Related]

  • 2. Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells.
    Thompson JA, Benyunes MC, Bianco JA, Fefer A.
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):46-51. PubMed ID: 8284692
    [No Abstract] [Full Text] [Related]

  • 3. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
    Weiss GR, Margolin KA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, Gaynor ER, Boldt DH, Doroshow JH, Bar MH.
    J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
    [Abstract] [Full Text] [Related]

  • 4. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study.
    Negrier S, Philip T, Stoter G, Fossa SD, Janssen S, Iacone A, Cleton FS, Eremin O, Israel L, Jasmin C.
    Eur J Cancer Clin Oncol; 1989 Feb; 25 Suppl 3():S21-8. PubMed ID: 2697575
    [Abstract] [Full Text] [Related]

  • 5. Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma.
    Figlin RA, Pierce WC, Belldegrun A.
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):11-5. PubMed ID: 8284686
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
    Sznol M, Clark JW, Smith JW, Steis RG, Urba WJ, Rubinstein LV, VanderMolen LA, Janik J, Sharfman WH, Fenton RG.
    J Natl Cancer Inst; 1992 Jun 17; 84(12):929-37. PubMed ID: 1629914
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Renal cell carcinoma treated with continuous-infusion interleukin-2 with ex vivo-activated killer cells.
    Foon KA, Walther PJ, Bernstein ZP, Vaickus L, Rahman R, Watanabe H, Sweeney J, Park J, Vesper D, Russell D.
    J Immunother (1991); 1992 Apr 17; 11(3):184-90. PubMed ID: 1515423
    [Abstract] [Full Text] [Related]

  • 12. [Usefulness and limitation of immunotherapy of metastatic renal cell carcinoma with autologous lymphokine-activated killer cells and interleukin 2].
    Nakano E, Iwasaki A, Seguchi T, Sugao H, Tada Y, Matsuda M, Sonoda T.
    Nihon Hinyokika Gakkai Zasshi; 1991 Mar 17; 82(3):395-404. PubMed ID: 2072602
    [Abstract] [Full Text] [Related]

  • 13. Interleukin-2 immunotherapy followed by resection of residual renal cell carcinoma.
    Fleischmann JD, Kim B.
    J Urol; 1991 May 17; 145(5):938-41. PubMed ID: 2016805
    [Abstract] [Full Text] [Related]

  • 14. Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results.
    Tomita Y, Katagiri A, Saito K, Imai T, Saito T, Tanikawa T, Terunuma M, Nishiyama T, Takahashi K.
    Int J Urol; 1998 Jan 17; 5(1):16-21. PubMed ID: 9535595
    [Abstract] [Full Text] [Related]

  • 15. Survival characteristics of metastatic renal cell carcinoma patients treated with lymphokine-activated killer cells plus interleukin-2.
    Schoof DD, Terashima Y, Batter S, Douville L, Richie JP, Eberlein TJ.
    Urology; 1993 Jun 17; 41(6):534-9. PubMed ID: 8516989
    [Abstract] [Full Text] [Related]

  • 16. Treatment of advanced renal cell carcinoma using regional arterial administration of lymphokine-activated killer cells in combination with low doses of rIL-2.
    Hayakawa M, Hatano T, Ogawa Y, Gakiya M, Ogura H, Osawa A.
    Urol Int; 1994 Jun 17; 53(3):117-24. PubMed ID: 7645136
    [Abstract] [Full Text] [Related]

  • 17. Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma.
    Thompson JA, Bianco JA, Benyunes MC, Neubauer MA, Slattery JT, Fefer A.
    Cancer Res; 1994 Jul 01; 54(13):3436-41. PubMed ID: 8012963
    [Abstract] [Full Text] [Related]

  • 18. Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen.
    Parkinson DR, Fisher RI, Rayner AA, Paietta E, Margolin KA, Weiss GR, Mier JW, Sznol M, Gaynor ER, Bar MH.
    J Clin Oncol; 1990 Oct 01; 8(10):1630-6. PubMed ID: 2213100
    [Abstract] [Full Text] [Related]

  • 19. Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid.
    Atzpodien J, Kirchner H, Duensing S, Lopez Hänninen E, Franzke A, Buer J, Probst M, Anton P, Poliwoda H.
    World J Urol; 1995 Oct 01; 13(3):174-7. PubMed ID: 7550391
    [Abstract] [Full Text] [Related]

  • 20. Randomized study of interleukin 2 (IL-2) alone vs IL-2 plus lymphokine-activated killer cells for treatment of melanoma and renal cell cancer.
    Koretz MJ, Lawson DH, York RM, Graham SD, Murray DR, Gillespie TM, Levitt D, Sell KM.
    Arch Surg; 1991 Jul 01; 126(7):898-903. PubMed ID: 1854252
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.